Jeffrey Davis, MD
Orthopaedic Surgery · Birmingham, ALNPI 1538198189
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (42.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Encore Medical, LP accounts for 80.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $3,684 and has fallen 84.8% since, to $560 in 2025.
Across 32 payments — averaging $140.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Encore Medical, LP$4K
- Osteoremedies, LLC$166
- Orthalign Inc$147
- Smith+Nephew$144
- Stryker$114
- Johnson & Johnson$71
- plus $230 from 10 others
Across 10 payments — averaging $28,879 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$275K
- Pacira Therapeutics, Inc.$11K
- Biotissue Holdings Inc.$3K
What the payments were for
- Speaking & faculty fees$1,50033%
- Travel & lodging$1,92343%
- Food & beverage$1,06324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Encore Medical, LP | 13 | $3,614 |
| Osteoremedies, LLC | 1 | $166 |
| Orthalign Inc | 1 | $147 |
| Smith+Nephew | 1 | $144 |
| Stryker | 3 | $114 |
| Johnson & Johnson | 1 | $71 |
| Getinge USA Sales, LLC | 1 | $40 |
| Heron Therapeutics, Inc. | 2 | $30 |
| Convatec Inc. | 2 | $30 |
| Conmed Corporation | 1 | $23 |
| Bioventus LLC | 1 | $20 |
| Vertex | 1 | $20 |
| BD | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Amgen | 1 | $16 |
| ERMI LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,487 in reported general payments places this provider in the 60th percentile of 319 orthopaedic surgery providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefadroxil | 167 | $1,540 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 194 | $1,282 |
| Methocarbamol | 96 | $688 |
| Celecoxib | 25 | $492 |
| Meloxicam | 124 | $418 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 40 | $364 |
| Mupirocin | 33 | $273 |
| Promethazine Hcl | 114 | $229 |
| Diclofenac Sodium | 19 | $188 |
| Doxycycline Hyclate | 13 | $99 |
| Cephalexin | 31 | $84 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 25 | $82 |
| Tramadol Hcl | 27 | $57 |
| Gabapentin | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Birmingham
- Jeffrey DugasBirmingham$11.5M
- Benton EmblomBirmingham$3M
- Herrick SiegelBirmingham$1.2M
- Kenneth MooreBirmingham$342K
- Joseph SherrillBirmingham$221K
- Jonathan QuadeBirmingham$217K
- Ginger BryantBirmingham$209K
- Marcus RothermichBirmingham$207K
- Daniel KimBirmingham$147K
- Eugene BrabstonBirmingham$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.